Results 191 to 200 of about 38,240 (235)

Trace-level determination of potential genotoxic impurities in quetiapine fumarate using LC-MS.

Biomedical chromotography, 2022
A novel LC-MS method was developed and validated to determine three potential genotoxic impurities, namely 2-(2-aminophenylthio)benzoic acid hydrochloride, 2-aminothiophenol, and 2-(2-aminophenylthio)benzonitrile, at trace level (~1.6 ppm) in quetiapine ...
DasameswaraRao Kavitapu, Ramana Reddy Gopireddy, Arthanareeswari Maruthapillai, J. Murty, N. K. Katari   +4 more
semanticscholar   +1 more source

The efficacy and tolerability of once-daily extended release quetiapine fumarate in hospitalized patients with acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled study.

Psychopharmacology bulletin
OBJECTIVES This study aimed to demonstrate efficacy of once-daily extended release quetiapine fumarate (quetiapine XR) versus placebo in patients with acute schizophrenia.
J. Lindenmayer, David Brown, S. Liu, M. Brecher, D. Meulien   +4 more
semanticscholar   +1 more source

Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release

Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009
This 10-day, single-center, open-label, randomized, crossover study compared pharmacokinetic profiles and tolerability of extended release quetiapine fumarate (quetiapine XR) with quetiapine immediate release (quetiapine IR) in patients with schizophrenia, schizoaffective disorder or bipolar disorder.
Carlos, Figueroa, Martin, Brecher, Jennifer E, Hamer-Maansson, Helen, Winter   +3 more
openaire   +2 more sources

A failed 6-week,randomized, double-blind, placebo-controlled study of once-daily extended release quetiapine fumarate in patients with acute schizophrenia: lessons learned.

Psychopharmacology bulletin
OBJECTIVE To demonstrate the efficacy of once-daily extended release quetiapine fumarate (quetiapine XR) versus placebo in adults with acute exacerbation of schizophrenia. METHODS A 6-week, double-blind, randomized, placebo-controlled study. In- or out-
A. Cutler, T. Tran-Johnson, A. Kalali, M. Åström, M. Brecher, D. Meulien   +5 more
semanticscholar   +1 more source

Identification and Characterization of Potential Impurities of Quetiapine Fumarate

Pharmaceutical Development and Technology, 2008
Seven potential impurities, including by-products, starting materials and intermediates were identified in pharmaceutical substance quetiapine fumarate and characterized by spectroscopic methods (MS, IR, NMR). Based on these methods the structures of the impurities were assigned or confirmed as: impurity I: 2-(phenylthio)aniline; impurity II: phenyl N-[
Elzbieta U, Stolarczyk, Lukasz, Kaczmarek, Kamil, Eksanow, Marek, Kubiszewski, Magdalena, Glice, Andrzej, Kutner   +5 more
openaire   +2 more sources

Pharmacokinetic profile of the extended-release formulation of quetiapine fumarate (quetiapine XR): clinical implications

Current Medical Research and Opinion, 2013
A series of studies were conducted to guide the development and characterise the pharmacokinetics of extended-release quetiapine fumarate (quetiapine XR), a once-daily formulation to control the release of the drug.Data from these studies are described and discussed herein.Once-daily quetiapine XR produced a similar area under the plasma concentration ...
Khanh, Bui, Willie, Earley, Svante, Nyberg   +2 more
openaire   +2 more sources

Development and characterization of polymeric nanosponges for enhanced solubility of quetiapine fumarate

Particulate Science and Technology
Quetiapine fumarate (QTF), a second-generation antipsychotic used for the treatment of schizophrenia, suffers from poor aqueous solubility and low oral bioavailability.
R. Mutha, S. Nangare, P. Bafna, Prashant Patil, V. Bagul, Rupal Jain, Ganesh Patil   +6 more
semanticscholar   +1 more source

Fabrication and characterization of nanostructured lipid carrier system for effective delivery of poorly water-soluble drug quetiapine fumarate

Research Journal of Pharmacy and Technology, 2021
The aim of present study is to investigate the potential of nanostructured lipid carriers (NLCs) in improving the oral bioavailability of quetiapine fumarate, a second-generation antipsychotic drug.
D. Patil, Seema V. Pattewar, Sarvesh Palival, G. Patil, Swapnil Sharma   +4 more
semanticscholar   +1 more source

Quetiapine fumarate overdose: Clinical and pharmacokinetic lessons from extreme conditions

Clinical Pharmacology & Therapeutics, 2000
Although the new atypical antipsychotic, quetiapine fumarate, is growing in popularity over its progenitor, clozapine, clinical experience with overdose of this agent remains limited. Observation of an overdose situation provided a unique opportunity to define the safety, clinical effects, and pharmacokinetics of this medication more clearly.A patient ...
P T, Pollak, K, Zbuk
openaire   +2 more sources

Quetiapine fumarate (Seroquel(R)): A new atypical antipsychotic

Drugs of Today, 1999
The goal of antipsychotic drug development efforts over the past 10 years has been to develop agents with increased efficacy and safety and fewer of the side effects commonly associated with the older antipsychotic medications. The newer agents, often called atypical antipsychotics, are effective in treating both the positive and negative symptoms of ...
openaire   +2 more sources